drugset / Trial / NCT05244837
Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To explore the related biomarkers for safety and efficacy of the combination of chemotherapy and tislelizumab in non-small cell lung cancer
Timeline
- Start
- 2020-12-22
- Primary completion
- 2022-07
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.